Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canagliflozin in diabetic nephropathy
NCT03436693Phase 3Completed
- Sponsor
- Mitsubishi Tanabe Pharma
- Start
- Feb 2018
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of canagliflozin in diabetic nephropathy (DN), sponsored by Mitsubishi Tanabe Pharma. Started Feb 2018; status: completed.
02
Drugs
canagliflozin
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT03436693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03436693.